Cancer drugs to get cheaper in India by up to ₹72,900

National Pharmaceutical Pricing Authority (NPPA) revised MRPs of 543 formulations of 137 cancer drugs that previously had no government-fixed price ceiling. The chemotherapy drug thiotepa saw the biggest price drop in rupees terms, falling by ₹72,921.53, while breast cancer drug palbociclib saw the biggest percentage drop of 93.3%. Patients are expected to save up to ₹2,500-₹3,500 crore annually.